Explore the Agenda
7:00 am Check-In & Light Breakfast
8:10 am Chair’s Opening Remarks
Advancing Breakthrough Precision Medicine Trials Revealing Earlier, Actionable Treatment Signals & Delivering More Personalized, Impactful Patient Care
8:15 am Enabling Access to Novel Computational Biomarkers: From Innovation to Impact
- Discussing how computational pathology can move beyond the limits of the human eyesight and the light microscope
- Examining real-world performance of the TROP2-NMR QCS algorithm
- Enabling global access to computational pathology
8:35 am Session Reserved for Natera
Presentation Details to be Announced
9:05 am Valuing Academic Precision Medicine Industry Partnerships
- Defining the shared value of academic–industry precision medicine partnerships across research, education, and real-world impact
- Evaluating common risks (e.g. IP, data ownership, conflicts of interest) and strategies to mitigate them
- Reviewing case examples of successful collaborations in digital pathology
9:25 am Breaking Barriers in Precision Oncology: One Global Companion Diagnostic Platform Across Liquid & Tissue
- Guardant Health will highlight our latest global CDx regulatory approvals and advancements toward a unified platform spanning both liquid and tissue testing
- This session will showcase how Guardant Health is enabling a more streamlined, scalable, and globally consistent approach to precision oncology by delivering integrated CDx solutions across technologies, indications, and geographies
9:55 am Morning Break & Refreshments
10:20 am One-to-One Meetings & Structured Networking
A dedicated window for strategic one-on-one discussions and targeted networking, enabling attendees to strengthen key relationships and have purposeful conversations that drive meaningful outcomes in precision medicine
Developing Strategic & Practical Drug-Diagnostic Co-Development Playbooks Across Translational, Clinical, Regulatory & Commercial Teams to Ensure Scalable, Compliant Precision Medicine Programs
10:40 am Session Reserved for Roche
Presentation Details to be Announced
11:10 am Building High Impact Companion Diagnostics Alliances: Partnering Models that Accelerate Precision Oncology from Development to Delivery
- Exploring Johnson & Johnson’s Pharma–Diagnostics Partnership Model: An overview of how J&J structures and enables early, aligned collaboration between drug and diagnostics teams and external partners to support integrated decision making, development strategies, and regulatory readiness
- Showcasing Insights from Successful Precision Oncology Programs: Learnings drawn from delivering CDx-enabled oncology programs, highlighting the partnership approaches that help translate scientific innovation into meaningful real-world impact
- Looking Ahead – How Precision Medicine Partnerships are Evolving Across the Industry: A broader perspective on where pharma-diagnostics partnering is headed, and key considerations for delivering CDx-enabled therapies at scale across patients, clinicians and health systems
11:30 am Session Reserved for Foundation Medicine
Presentation Details to be Announced
12:00 pm Panel Discussion: Liquid Biopsy at the Point of Care: Making ctDNA Actionable for Treatment Selection
- Where We Are Today: Real‑world use of liquid biopsy across biomarker selection, resistance detection at progression, and treatment response/MRD monitoring
- What’s Holding Adoption Back (And Where it’s Worst): Evidence and guideline clarity, reimbursement and logistics, workflow integration, and report interpretability, with a focus on medically underserved settings and populations
- How We Move the Needle: Oncologist perspectives on what would most increase willingness and ability to order, interpret, and act on results, with practical actions for biopharma, diagnostics, and health systems
12:30 pm Session Reserved for Agilent Technologies
Presentation Details to be Announced
1:00 pm Lunch Break & Networking
1:00 pm Lunch & Learn Hosted By Quest Diagnostics
*Invitation only
1:30 pm One-to-One Meetings & Structured Networking
Orchestrating the End-to-End Rx-Dx Lifecycle: Advancing Co-Development, Clinical Integration & Access to Deliver Scalable, Patient-Centric Precision Therapies
2:00 pm Single-Cell Becomes a Reality: The Next Generation of Therapy Selection Biomarkers
- Advances in wet lab and bioinformatics enabling single-cell use in the clinic
- Clinical programs currently developing single-cell biomarkers
- Outlook on single-cell deployment in the clinic and as CDx
2:30 pm Integrating Science & Strategy to Advance Companion Diagnostic Development for Optimal Patient Treatment
- Discussing how CDx offer the ability to select optimal treatments for each patient based on biology, while the field continues to expand rapidly amid technological and regulatory change
- CDx development must balance optimal test performance, ideal technologies, and innovative approaches with global accessibility, testing paradigm fit, development and test cost, while fulfilling regulatory requirements
- Showcasing how technologies such as digital pathology with AI and ML-based interpretation, ctDNA, and multiplex assays offer the potential for increased accuracy in supporting optimal treatment selection for each patient, but each presents its own challenges
2:50 pm Beyond Detection: The Role of Multi-Cancer Early Detection (MCED) in Advancing Oncology Trial Execution
- Emerging Galleri clinical evidence and its relevance to oncology development
3:20 pm Do We Need Enrichment? Clinical & Translational Learnings from Amgen T-Cell Engagers
- Tarlatamab and xaluritamig (STEAP1) demonstrate clinical activity across a broad range of target expression levels, with no clear IHC cut-off for response
- Beyond tumor antigen expression, what alternative determinants may drive response or resistance?
- To what extent might factors such as the tumor microenvironment, immune cell fitness, or other non-target antigen features influence clinical benefit?
3:40 pm Access & Optionality: Expanding Patient Reach Through Integrated Companion Diagnostic & Laboratory-Developed Test (LDT) Strategies
- As precision medicine advances, CDx are increasingly essential, but are often perceived as a bottleneck to patient access
- Explore how an integrated approach can turn that challenge into an opportunity
- Learn how Quest BioPharma Services enables both CDx and LDT pathways under one roof, offering flexibility across the drug development and commercialization lifecycle
4:10 pm Afternoon Break & Dedicated One-to-One Meetings
Building Standardized ctDNA & MRD Strategies to Strengthen Clinical Development Rigor & Provide High‑Integrity, Actionable
Patient‑Response Insights
4:40 pm Clinical Validation of Myriad Genetics’ Ultra-Sensitive Pan-Cancer WGS-Based Precise MRD Assay
- Understand how ultra-sensitive, tumor-informed MRD testing is being applied across clinical and development settings
- Walk away with a clear view of where ultra-sensitive MRD testing delivers value today and how to apply it across your own programs
5:10 pm Panel Discussion: Has Companion Diagnostics Outgrown Its Origins?
Presentation Details to be Announced
5:40 pm Session Reserved for SOPHiA GENETICS
Presentation Details to be Announced
6:10 pm Panel Discussion: Strengthening Tumor‑Informed MRD Assays with Standardized Analytical Validation to Ensure Reliable Detection & Confident Clinical Interpretation
- What factors define intended use for MRD at predefined post-surgery time points and how to align study designs to qualitative detection endpoints?
- How to design precision repeatability and reproducibility across instruments, operators and sites under clinical sample scarcity?
- How can assay accuracy be robustly established when orthogonal reference methods are less sensitive than the MRD assay?
6:30 pm Closing Remarks & End of Conference Day One
7:30 - 10:00
Hosted Reception Engager in Partnership with Myriad Genetics & SOPHiA GENETICS
